During periods of hyperglycemia, GLP-1 receptor activation of the insulin secretory response is increased, and the development of GLP-1 receptor agonists has evolved as a breakthrough for the treatment of type 2 diabetes and, more recently, obesity. Here, GLP1R is linked to obesity disorder.